The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease

Current Opinion in Cardiology

Volumn 23, Issue 5, 2008, Pages 487-493

  Lotrionte, Marzia ^a   Biondi Zoccai, Giuseppe G L ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Acetylsalicylic acid; Aspirin; Coronary artery disease; Percutaneous transluminal coronary angioplasty

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RAPAMYCIN; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BARE METAL STENT; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HAZARD ASSESSMENT; HEART MUSCLE REVASCULARIZATION; HUMAN; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCIENTIFIC LITERATURE; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; STENT THROMBOSIS; SURGICAL RISK; THROMBOSIS; TREATMENT DURATION; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT WITHDRAWAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY ARTERY DISEASE; HUMANS; PATIENT COMPLIANCE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; WITHHOLDING TREATMENT;

EID: 56449109534     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32830b5afa     Document Type: Review

References (20)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71 -86.
2. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27:2667-2674.
3. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117:73-81.
4. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151:185-191.
5. Biondi-Zoccai GG, Testa L, Agostoni P. A practical algorithm for systematic reviews in cardiovascular medicine. Ital Heart J 2004; 5:486-487.
6. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116:745-754.
7. Brotman DJ, Bakhru M, Saber W, et al. Discontinuation of antiplatelet therapy prior to low-risk noncardiac surgery in patients with drug-eluting stents: a retrospective cohort study. J Hosp Med 2007; 2:378-384.
8. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297:2018-2024.
9. Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532-539.
10. Kim HL, ParkKW, KwakJJ, et al. Stent-related cardiac events after noncardiac surgery: drug-eluting stent vs. bare metal stent. Int J Cardiol 2008; 123:353-354.
11. Moriel M, Tzivoni D, Behar S, et al. Contemporary treatment and adherence to guidelines in women and men with acute coronary syndromes. Int J Cardiol 2008. [Epub ahead of print; doi:10.1016/j.ijcard.2007.09.005]
12. Renda G, Di Pillo R, D'Alleva A, et al. Surgical bleeding after preoperative unfractionated heparin and low molecular weight heparin for coronary bypass surgery. Haematologica 2007; 92:366-373.
13. Szalat A, Erez G, Leitersdorf E. Aspirin withdrawal prior to invasive medical procedures: a strategy based on thromboembolic and bleeding risk stratification. Isr Med Assoc J 2007; 9:435-438.
14. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007; 50:138-145.
15. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, et al., TRUE (Taxus in Real-Life Usage Evaluation) Study Investigators. Comparison of ticlopidine vs. clopi-dogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxus in Real-life Usage Evaluation) Study. Int J Cardiol 2006; 108:406-407.
16. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression. Am Heart J 2007; 153:587-593.
17. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials: proposal of a new classification. Am J Cardiol 2007; 99:288-290.
18. Nikolsky E, Mehran R, Dangas G, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28:1936-1945.
19. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001; 141:190-199.
20. Biondi-Zoccai G, Lotrionte M. Aspirin resistance in cardiovascular disease. BMJ 2008; 336:166-167.